824 related articles for article (PubMed ID: 21357827)
1. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
[TBL] [Abstract][Full Text] [Related]
2. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
[TBL] [Abstract][Full Text] [Related]
3. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
Anderson C; Teo K; Gao P; Arima H; Dans A; Unger T; Commerford P; Dyal L; Schumacher H; Pogue J; Paolasso E; Holwerda N; Chazova I; Binbrek A; Young J; Yusuf S;
Lancet Neurol; 2011 Jan; 10(1):43-53. PubMed ID: 20980201
[TBL] [Abstract][Full Text] [Related]
4. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET).
Kappert K; Böhm M; Schmieder R; Schumacher H; Teo K; Yusuf S; Sleight P; Unger T;
Circulation; 2012 Aug; 126(8):934-41. PubMed ID: 22829023
[TBL] [Abstract][Full Text] [Related]
5. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.
Böhm M; Baumhäkel M; Teo K; Sleight P; Probstfield J; Gao P; Mann JF; Diaz R; Dagenais GR; Jennings GL; Liu L; Jansky P; Yusuf S;
Circulation; 2010 Mar; 121(12):1439-46. PubMed ID: 20231536
[TBL] [Abstract][Full Text] [Related]
6. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
Yu LT; Zhu J; Tan HQ; Wang GG; Teo KK; Liu LS
Chin Med J (Engl); 2011 Jun; 124(12):1763-8. PubMed ID: 21740829
[TBL] [Abstract][Full Text] [Related]
7. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
Verdecchia P; Sleight P; Mancia G; Fagard R; Trimarco B; Schmieder RE; Kim JH; Jennings G; Jansky P; Chen JH; Liu L; Gao P; Probstfield J; Teo K; Yusuf S;
Circulation; 2009 Oct; 120(14):1380-9. PubMed ID: 19770395
[TBL] [Abstract][Full Text] [Related]
8. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Mann JF; Schmieder RE; McQueen M; Dyal L; Schumacher H; Pogue J; Wang X; Maggioni A; Budaj A; Chaithiraphan S; Dickstein K; Keltai M; Metsärinne K; Oto A; Parkhomenko A; Piegas LS; Svendsen TL; Teo KK; Yusuf S;
Lancet; 2008 Aug; 372(9638):547-53. PubMed ID: 18707986
[TBL] [Abstract][Full Text] [Related]
9. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
[TBL] [Abstract][Full Text] [Related]
10. Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs.
Diener HC
J Hypertens Suppl; 2009 Jul; 27(5):S31-6. PubMed ID: 19587553
[TBL] [Abstract][Full Text] [Related]
11. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.
Clase CM; Barzilay J; Gao P; Smyth A; Schmieder RE; Tobe S; Teo KK; Yusuf S; Mann JF
Kidney Int; 2017 Mar; 91(3):683-690. PubMed ID: 27927602
[TBL] [Abstract][Full Text] [Related]
12. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
Böhm M; Schumacher H; Teo KK; Lonn EM; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder RE; Sliwa K; Weber MA; Williams B; Yusuf S
Lancet; 2017 Jun; 389(10085):2226-2237. PubMed ID: 28390695
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan for the management of patients at high cardiovascular risk.
Ruilope LM
Curr Med Res Opin; 2011 Aug; 27(8):1673-82. PubMed ID: 21718097
[TBL] [Abstract][Full Text] [Related]
14. The ONTARGET/TRANSCEND Trial Programme: baseline data.
Sleight P
Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
[TBL] [Abstract][Full Text] [Related]
15. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk.
Held C; Gerstein HC; Yusuf S; Zhao F; Hilbrich L; Anderson C; Sleight P; Teo K;
Circulation; 2007 Mar; 115(11):1371-5. PubMed ID: 17339550
[TBL] [Abstract][Full Text] [Related]
16. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
Cowan BR; Young AA; Anderson C; Doughty RN; Krittayaphong R; Lonn E; Marwick TH; Reid CM; Sanderson JE; Schmieder RE; Teo K; Wadham AK; Worthley SG; Yu CM; Yusuf S; Jennings GL;
Am J Cardiol; 2009 Dec; 104(11):1484-9. PubMed ID: 19932779
[TBL] [Abstract][Full Text] [Related]
17. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
Unger T
Am J Cardiol; 2003 May; 91(10A):28G-34G. PubMed ID: 12781906
[TBL] [Abstract][Full Text] [Related]
18. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
Baumhäkel M; Böhm M
Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
[TBL] [Abstract][Full Text] [Related]
19. Telmisartan, ramipril, or both in patients at high risk for vascular events.
; Yusuf S; Teo KK; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P; Anderson C
N Engl J Med; 2008 Apr; 358(15):1547-59. PubMed ID: 18378520
[TBL] [Abstract][Full Text] [Related]
20. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).
Mancia G; Schumacher H; Redon J; Verdecchia P; Schmieder R; Jennings G; Yusoff K; Ryden L; Liu GL; Teo K; Sleight P; Yusuf S
Circulation; 2011 Oct; 124(16):1727-36. PubMed ID: 21947289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
